CAMRF (Camurus AB) Owner Earnings per Share (TTM): 1.37 (As of Mar. 2026) — 98% Below Median


CAMRF Camurus AB CAMRF
83 GF Score
Price $60.00
GF Value $83.37
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Owner Earnings per Share (TTM)?

Camurus AB CAMRF 83 Owner Earnings per Share (TTM) is 1.37 as of Mar. 2026, which is 98% below its 10-year median of 89.67. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $83.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 205 Biotechnology companies, Camurus AB ranks worse than 66.34% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Camurus AB's Owner Earnings per Share (TTM) ended in Mar. 2026 was $1.37. It's Price-to-Owner-Earnings ratio for today is 43.8.


The historical rank and industry rank for Camurus AB's Owner Earnings per Share (TTM) or its related term are showing as below:

CAMRF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 37.54   Med: 89.67   Max: 717.78
Current: 43.74


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Camurus AB was 717.78. The lowest was 37.54. And the median was 89.67.


CAMRF's Price-to-Owner-Earnings is ranked worse than
66.34% of 205 companies
in the Biotechnology industry
Industry Median: 24.44 vs CAMRF: 43.74

Camurus AB's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $0.26. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.21. It's PE Ratio (TTM) ratio for today is 49.79.

Camurus AB's EPS without NRI for the three months ended in Mar. 2026 was $0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.21. It's PE Ratio without NRI ratio for today is 49.79.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Camurus AB Owner Earnings per Share (TTM) Related Terms


Camurus AB Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Camurus AB's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Owner Earnings per Share (TTM) Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 0.06 0.28 0.35 1.21

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.92 0.86 1.21 1.52

CAMRF vs VRTX, REGN, ALNY: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Camurus AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Camurus AB's Price-to-Owner-Earnings falls into.


CAMRF
83GF Score
Camurus AB CAMRF
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Camurus AB's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 72.5
Depreciation, Depletion and Amortization 2.8
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 4.0
Change In Working Capital 10.9
Shares Outstanding (Diluted Average) 59.8

1. Start with "Net Income" from income statement. Camurus AB's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was $72.5 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Camurus AB's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was $2.8 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Camurus AB's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $4.0 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Camurus AB's 5-Year Average Maintenance Capital Expenditure = $4.0 Mil

5. "Change In Working Capital" is from cashflow statement. Camurus AB's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was $10.9 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Camurus AB's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 59.829 Mil.

Camurus AB's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 72.482 +2.798+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-4.021057843304+10.892)/59.829
=1.37

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=60.00/1.37
=43.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 1.37 mean?
Camurus AB (CAMRF) has a Owner Earnings per Share (TTM) of 1.37 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Camurus AB. This is 98% below median its historical median of 89.67. Over the past decade, Camurus AB's Owner Earnings per Share (TTM) has ranged from 37.54 to 717.78. According to the industry distribution chart, Camurus AB ranks #136 out of 205 companies in the Biotechnology industry, placing it in the top 66.3%.
Is Camurus AB's Owner Earnings per Share (TTM) too high?
Camurus AB's current Owner Earnings per Share (TTM) of 1.37 is 98% below median its 10-year median of 89.67. Over the past 10 years, this metric has ranged from a low of 37.54 to a high of 717.78. The Biotechnology industry median Owner Earnings per Share (TTM) is 24.44. Camurus AB's value of 1.37 is 94.4% below this industry median. Based on the distribution chart, Camurus AB ranks #136 out of 205 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Owner Earnings per Share (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #136 out of 205 companies for Owner Earnings per Share (TTM). This places Camurus AB in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.44. Camurus AB's value of 1.37 is 94.4% below this benchmark. Historically, Camurus AB's own Owner Earnings per Share (TTM) has ranged from 37.54 to 717.78 over the past decade. While the company's 10-year median is 89.67 vs. the industry median of 24.44, Camurus AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 24.44, based on 205 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Owner Earnings per Share (TTM) of 1.37 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Camurus AB. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 24.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Owner Earnings per Share (TTM) is 1.37, which is 98% below median its own 10-year median of 89.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.37, compared to a current price of $60.00 — trading 28% below its estimated fair value. The current Owner Earnings per Share (TTM) is 1.37, which is 98% below median its 10-year median of 89.67 and 94.4% below the Biotechnology industry median of 24.44. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Owner Earnings per Share (TTM) is 1.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $60.00 is trading 28% below its estimated GF Value™ of $83.37. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • Owner Earnings per Share (TTM): 1.37 (98% below median its 10-year median of 89.67)
  • GF Value™: $83.37 vs. price of $60.00 (28% below fair value)
  • GF Score™: 83/100 with 1 warning sign
  • Industry Position: 94.4% below the Biotechnology median (#136 of 205)

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score

Get the complete analysis for CAMRF

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.00
Price
$83.37
GF Value